Cooper Companies Inc(COO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 5:10 PM ET (Korea 9/12 06:10)
Full metrics table
| Index | S&P 500 | P/E | 18.38 | EPS (ttm) | 2.93 | Insider Own | 0.6% | Shs Outstand | 195.0M | Perf Week | -23.74% |
| Market Cap | 10.24B | Forward P/E | 11.45 | EPS next Y | 3.6% | Insider Trans | - | Shs Float | 193.8M | Perf Month | -29.79% |
| Enterprise Value | 12.63B | PEG | 1.55 | EPS next Q | 1.08 | Inst Own | 109.88% | Short Float | 4.53% | Perf Quarter | -20.2% |
| Income | 0.57B | P/S | 2.42 | EPS this Y | 10.26% | Inst Trans | 2.3% | Short Ratio | 3.37 | Perf Half Y | -24.68% |
| Sales | 4.24B | P/B | 1.23 | EPS next 5Y | 7.39% | ROA | 4.55% | Short Interest | 8.78M | Perf YTD | -34.27% |
| Book/sh | 43.81 | P/C | 66.13 | EPS past 3/5Y | -1.15% 9.3% | ROE | 6.84% | 52W High | -40.03% ($89.83) | Perf Year | -21.31% |
| Cash/sh | 0.81 | P/FCF | 15.11 | Sales past 3/5Y | 7.35% 10.98% | ROIC | 5.57% | 52W Low | 5.61% ($51.01) | Perf 3Y | -38.71% |
| Dividend Est. | - | EV/EBITDA | 10.53 | EPS Y/Y TTM | 43.89% | Gross Margin | 61.39% | Volatility(W/M) | 4.71% 2.53% | Perf 5Y | -52.26% |
| Dividend TTM | - | EV/Sales | 2.98 | Sales Y/Y TTM | 4.73% | Oper. Margin | 19.26% | ATR (14) | 2.62 | Perf 10Y | 16.58% |
| Dividend Ex-Date | 2023/7/26 | Quick Ratio | 0.73 | EPS Q/Q | 355.3% | Profit Margin | 13.46% | RSI (14) | 14.49 | Recom | 2.37 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.22 | Sales Q/Q | 0.56% | SMA20 | -23.5% ($70.42) | Beta | 0.84 | Target Price | $65.85 |
| Payout | - | Debt/Eq | 0.31 | Earnings | 2026/9/9 | SMA50 | -24.88% ($71.71) | Rel Volume | 2.47 | Prev Close | $54.17 |
| Employees | 15000 | LT Debt/Eq | 0.23 | EPS/Sales Surpr. | 2.34% -2.93% | SMA200 | -26.33% ($73.12) | Avg Volume(3M) | 2.61M | Price | $53.87 |
| IPO | 1983/1/21 | Option/Short | Yes/Yes | Trades | 51618 | Volume | 6,435,818 | Change | -0.55% |
Company
COO is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A U.S. medical device company, it operates a global contact lens and women's health medical device business, combining a vision correction business centered on contact lenses with medical devices related to women's health and infertility treatment. Its pediatric myopia management lenses are growing.
Over the past 1 year, on the lower side
40% below its 1-year high.
COO earns at a steady pace
19.26% of revenue is kept as operating profit.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +10.3% this year.
Tap to view numbers
The stock looks undervalued
Trading at 18.4 times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -38.7% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 109.9%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
KMID 0.03%
BASV 0.02%
MDEV 0.02%
EQTY 0.02%
XHE 0.02%It ranks #4 in the industry
Based on market cap of $10B.
COO $10B PER 18.4
ISRG $131B PER 42.4
BDX $48B PER 53.6
MDLN $43B PER 38.1
FAQ
What kind of company is COO?
COO belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of COO?
The market cap of COO is approximately $10.2B, ranking 930 within its sector.
What is the P/E ratio of COO?
COO has a P/E ratio of approximately 18.4x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for COO?
COO has recorded a 52-week high of $89.83 and a low of $51.01.
